Research Library › Neuropeptides
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) made by adding a stabilizing Pro-Gly-Pro tail to tuftsin, a four-amino-acid fragment of an antibody chain. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences with the Zakusov Institute of Pharmacology, with patents dating to 1983 and 1999. It is sold without prescription in Russia but is not FDA-approved and was not among the peptides the FDA reviewed in 2026.
Key facts
| Type | Synthetic seven-amino-acid peptide (heptapeptide) |
|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Derived from | Tuftsin (Thr-Lys-Pro-Arg), a fragment of the immunoglobulin G heavy chain, plus a Pro-Gly-Pro tail |
| First described | USSR patent with 1983 priority; second Russian patent in 1999 |
| Developed by | Institute of Molecular Genetics (Russian Academy of Sciences) with the Zakusov Institute of Pharmacology; inventors include N.F. Myasoedov and S.B. Seredenin |
| Designed target | Proposed interaction with GABA-A receptor and serotonin systems (unconfirmed) |
| Regulatory status (Oct 2026) | Not FDA-approved; over-the-counter medicine in Russia; not reviewed by FDA's compounding advisory committee in 2026 |
Who developed it
Selank was created by the same Moscow peptide-chemistry group that produced Semax, at the Institute of Molecular Genetics of the Russian Academy of Sciences, working together with the Zakusov Institute of Pharmacology. The inventors named on its 1999 Russian patent include Nikolay Myasoedov and Sergei Seredenin [1][2].
Myasoedov, a long-serving academician of the Russian Academy of Sciences, has described the institute’s broader program of building short, regulatory peptides from naturally occurring sequences and stabilizing them with proline-rich tails [2]. Selank and Semax are the two best-known molecules from that program.
What it was designed to target
The parent molecule is tuftsin, a natural four-amino-acid peptide (Thr-Lys-Pro-Arg) released from the heavy chain of immunoglobulin G. Tuftsin was identified in 1970 by Victor Najjar’s group and named after Tufts University, where the work was done. It was characterized as a signal that stimulates phagocytic immune cells [3].
Because short peptides like tuftsin are broken down quickly, the Moscow team appended the Pro-Gly-Pro tripeptide, the same stabilizing tail used in Semax, giving a seven-residue molecule [4].
Its mechanism remains a proposal. Cell and animal studies by the developers explored possible interactions with the GABA-A receptor system and serotonin signaling, including gene-expression work in the frontal cortex and hippocampus of rodents [4][5]. In a 2017 cell-line study from the same group, Selank on its own did not change expression of the GABA-pathway genes measured [4].
Why it was created
Selank has an unusual patent history. The original USSR patent, with a 1983 priority date, described the peptide in the context of memory research. In 1999 its developers filed a new Russian patent for the same molecule in a research program on anxiety, noting that this application had previously been unknown [1]. The aim of that later program was a compound distinct from benzodiazepine-type drugs [1][4].
Research timeline
- 1970: Tuftsin, the parent peptide, is discovered [3].
- 1983: Priority date of the USSR patent covering the tuftsin analog [1].
- 1999: Second Russian patent filed, for an anxiety-related application [1].
- 2016–2017: Developers publish gene-expression studies on GABA-related pathways [4][5].
- Today: Registered in Russia as a non-prescription medicine [6].
Regulatory status as of October 2026
As of 22 Oct 2026, Selank is registered in Russia, where it is sold without prescription by Peptogen for an indication related to anxiety [6]. It is not FDA-approved in the United States.
Selank was not among the seven peptides evaluated by the FDA’s Pharmacy Compounding Advisory Committee in July 2026, nor among the peptides discussed in the FDA’s April 2026 Category 2 list update [7][8]. No FDA decision on its compounding status had been announced as of 22 Oct 2026.
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed Selank?
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with the Zakusov Institute of Pharmacology. Inventors on its patent include N.F. Myasoedov and S.B. Seredenin.
What is Selank derived from?
Selank is derived from tuftsin, a four-amino-acid fragment of immunoglobulin G, with a Pro-Gly-Pro tail added for stability.
Is Selank FDA approved?
No. As of 22 Oct 2026 Selank is not FDA-approved, and it was not among the peptides reviewed by the FDA’s compounding advisory committee in 2026.
What is the difference between Selank and Semax?
Both come from the same Moscow institute and share the Pro-Gly-Pro tail. Selank is built on the immune peptide tuftsin, while Semax is built on a fragment of the hormone ACTH.
When was Selank first patented?
The underlying USSR patent has a priority date of 30 June 1983. A second Russian patent covering the same molecule was filed in April 1999.
Sources
- Andreeva LA, Myasoedov NF, Seredenin SB et al. Anxiolytic agent and pharmaceutical composition with anxiolytic effect. Patent RU2155065C1 (priority 23 Apr 1999); cites USSR patent 1124544 (priority 30 Jun 1983). Link
- Myasoedov NF, Kost NV. Interview with Academician of RAS Nikolay F. Myasoedov. Psychiatry (Moscow). 2025;23(2):13–15. Link
- Siemion IZ, Kluczyk A. Tuftsin: on the 30-year anniversary of Victor Najjar's discovery. Peptides. 1999;20:645–674. Link
- Filatova E et al. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89. PMID 28293190. Link
- Volkova A et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031 Link
- Medi.ru. Selank: instructions for use (Peptogen; sold without prescription). Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
